HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Estrogen therapy in postmenopausal osteoporosis. What we know and what we don't.

Abstract
Replacement estrogen therapy is of proven efficacy for the prevention and treatment of postmenopausal bone loss. Oral and transdermal 17 beta estradiol have provided similar benefits in clinical studies. The lowest effective doses are 0.625 mg per day for conjugated estrogens, 2 mg per day for oral 17 beta estradiol, 1.5 micrograms per day for 17 beta estradiol gel, and 50-microgram 17 beta estradiol patch per day. Bone mineral density should be monitored if lower doses are used. Several epidemiologic studies found that a decrease in the incidence of osteoporotic fractures was achieved only when the duration of estrogen replacement therapy exceeded seven years. It follows that replacement therapy should be started at cessation of menses, if possible. However delayed replacement therapy (i.e., at 65 years of age) is unquestionably effective.
AuthorsC Roux
JournalRevue du rhumatisme (English ed.) (Rev Rhum Engl Ed) Vol. 64 Issue 6 Pg. 402-9 (Jun 1997) ISSN: 1169-8446 [Print] France
PMID9513613 (Publication Type: Journal Article, Review)
Topics
  • Aged
  • Estrogen Replacement Therapy
  • Female
  • Humans
  • Middle Aged
  • Osteoporosis, Postmenopausal (drug therapy, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: